NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Trial finds no benefit from using colchicine in hospitalised COVID-19 patients

Trial finds no benefit from using colchicine in hospitalised COVID-19 patients

19 May 2021 · Listed under COVID-19, Translational Data Science

The RECOVERY Trial, the world’s largest randomised trial of potential COVID-19 treatments, has found no evidence that that the drug colchicine has any meaningful clinical benefits for patients hospitalised with COVID-19.

Packet of colchicine tablets
image: wikimedia commons

Colchicine is used to treat inflammation and pain in conditions such as gout. Because of its anti-inflammatory qualities, it had been proposed as a potential treatment for COVID-19.

However, in a paper published on the pre-print server medRxiv, the Oxford-led team said that the drug had resulted in no significant reduction in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

A total of 11,340 patients hospitalised with COVID-19 were randomised to the colchicine arm of the trial.

The RECOVERY trial’s Joint Chief Investigator, Prof Martin Landray of the University of Oxford’s Nuffield Department of Population Health and the NIHR Oxford BRC’s Theme Lead for Clinical Informatics and Big Data, said: “Like every drug we’ve studied, there were sound reasons for thinking colchicine might work – we all hoped it would. So we did the trial and found out that colchicine doesn’t work, so it won’t be used. This is how we find better treatments. This is how we found that dexamethasone and tocilizumab save lives. This is how we reduce the devastation caused by COVID-19.

“As always, huge thanks to everyone involved: doctors, nurses, pharmacists, other healthcare professionals, research staff and so many more. But most especially to the thousands of patients who have taken part,” he added. The trial has recruited almost 40,000 participants across 181 NHS sites.

The trial has found two drugs – the steroid dexamethasone and tocilizumab, an intravenous drug used to treat rheumatoid arthritis – which do reduce the risk of death when given to patients hospitalised with severe COVID-19.

The trial has also announced results showing that the drugs hydroxychloroquine, lopinavir-ritonavir and azithromycin, as well as convalescent plasma have no benefits for patients hospitalised with COVID-19.

Among the potential treatments the trial is still studying are:

  • Regeneron’s antibody cocktail (a combination of monoclonal antibodies directed against coronavirus)
  • Baricitinib (an immunomodulatory drug used in rheumatoid arthritis)
  • Dimethyl fumarate (an immunomodulatory drug used in psoriasis and multiple sclerosis).

Read more about the RECOVERY trial.

← BRC researcher receives national infection prevention award
Study confirms longer-term lung damage after COVID-19 →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre